title: Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
mesh_terms: D002839:Chromans / Q000009:adverse effects*; D003257:Consumer Product Safety; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004345:Drug Industry; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008111:Liver Function Tests; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone; D014481:United States
chemical_list: D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077288:Troglitazone